{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:23:57Z","timestamp":1792178637448,"version":"4.4.0"},"reference-count":134,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["25-73-20033"],"award-info":[{"award-number":["25-73-20033"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>This review examines publications over the past two years devoted to histone deacetylase inhibitors for the treatment of cancer, diseases of the nervous, cardiovascular, digestive, and respiratory systems, and autoimmune diseases. The review covers various classes of histone deacetylase inhibitors depending on the zinc-binding group, in particular hydroxamic acids, benzamides, hydrazides, carboxylic acids, and cyclic peptides. The review pays special attention to the mechanisms of development of pathologies involving various isoforms of histone deacetylases. The review shows that, for the treatment of cancer, nervous, cardiovascular, respiratory systems, and autoimmune diseases, the most promising compounds are hydroxamic acids, and for the treatment of diseases of the digestive system, they are hydrazides and cyclic peptides. Variation in the linker and cap group of hydroxamic acids will allow the creation of an inhibitor selective for a specific histone deacetylase isoform. The review may be useful for molecular biologists, medical workers, and pharmacologists involved in the design of new drugs.<\/jats:p>","DOI":"10.3390\/ijms26178629","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T07:46:17Z","timestamp":1757058377000},"page":"8629","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Recent Insights into the Creation of Histone Deacetylase Inhibitors for the Treatment of Human Diseases"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8562-4696","authenticated-orcid":false,"given":"Pavel","family":"Yudaev","sequence":"first","affiliation":[{"name":"Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, Vavilova St., 28, Bld. 1, Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5370-3370","authenticated-orcid":false,"given":"Yulia","family":"Aleksandrova","sequence":"additional","affiliation":[{"name":"Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, Vavilova St., 28, Bld. 1, Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9346-5920","authenticated-orcid":false,"given":"Margarita","family":"Neganova","sequence":"additional","affiliation":[{"name":"Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, Vavilova St., 28, Bld. 1, Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Seto, E., and Yoshida, M. (2014). Erasers of Histone Acetylation: The Histone Deacetylase Enzymes. Cold Spring Harb. Perspect. Biol., 6.","DOI":"10.1101\/cshperspect.a018713"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13046-025-03335-5","article-title":"CD47 blockade reverses resistance to HDAC inhibitor by liberating anti-tumor capacity of macrophages","volume":"44","author":"Xu","year":"2025","journal-title":"J. Experim. Clin. Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"102032","DOI":"10.1016\/j.molmet.2024.102032","article-title":"Linking metabolism and histone acetylation dynamics by integrated metabolic flux analysis of Acetyl-CoA and histone acetylation sites","volume":"90","author":"Egger","year":"2024","journal-title":"Mol. Metabol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"116634","DOI":"10.1016\/j.ejmech.2024.116634","article-title":"Biological function and small molecule inhibitors of histone deacetylase 11","volume":"276","author":"Jia","year":"2024","journal-title":"Europ. J. Med. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Jing, Y., Li, X., Liu, Z., and Li, X.D. (2022). Roles of negatively charged histone lysine acylations in regulating nucleosome structure and dynamics. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.899013"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Zhang, X., Zhou, Y., Liu, Y., Li, B., Tian, S., and Zhang, Z. (2024). Research Progress on the Mechanism and Function of Histone Acetylation Regulating the Interaction between Pathogenic Fungi and Plant Hosts. J. Fungi, 10.","DOI":"10.3390\/jof10080522"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Patil, R.S., Maloney, M.E., Lucas, R., Fulton, D.J.R., Patel, V., Bagi, Z., Kovacs-Kasa, A., Kovacs, L., Su, Y., and Verin, A.D. (2024). Zinc-Dependent Histone Deacetylases in Lung Endothelial Pathobiology. Biomolecules, 14.","DOI":"10.20944\/preprints202401.0165.v1"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Kodikara, I.K., Nwanelo, V.O., Belanger, A.K., and Pflum, M.K.H. (2025). HDAC7 influences ER-\u237a transcription via NCoR-HDAC3 dissociation. Biochim. Biophys. Acta (BBA)-Prot. Proteom., 1873.","DOI":"10.1016\/j.bbapap.2025.141083"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Curcio, A., Rocca, R., Alcaro, S., and Artese, A. (2024). The histone deacetylase family: Structural features and application of combined computational methods. Pharmaceuticals, 17, Erratum in Pharmaceuticals 2024, 17, 1520.","DOI":"10.3390\/ph17111520"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/med.20056","article-title":"Targeting histone deacetylase in cancer therapy","volume":"26","author":"Lin","year":"2006","journal-title":"Med. Res. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/sj.cr.7310149","article-title":"HDACs, histone deacetylation and gene transcription: From molecular biology to cancer therapeutics","volume":"17","author":"Gallinari","year":"2007","journal-title":"Cell Res."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Yadalam, P.K., Ayyachamy, S., Barbosa, F.T., and Natarajan, P.M. (2025). Kolmogorov-Arnold networks for predicting drug-gene associations of HDAC1 inhibitors in periodontitis. Comput. Biol. Chem., 118.","DOI":"10.1016\/j.compbiolchem.2025.108451"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1007\/s12010-023-04731-3","article-title":"Screening of phytocompounds for identification of prospective histone deacetylase 1 (HDAC1) inhibitor: An in silico molecular docking, molecular dynamics simulation, and MM-GBSA approach","volume":"196","author":"Bharadwaj","year":"2024","journal-title":"Appl. Biochem. Biotechnol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"119666","DOI":"10.1016\/j.jep.2025.119666","article-title":"Xinyin tablets affect mitophagy and cardiomyocyte apoptosis to alleviate chronic heart failure by regulating histone deacetylase 3 (HDAC3)-mediated PTEN induced putative kinase 1 (PINK1)\/Parkin signaling pathway","volume":"346","author":"Chen","year":"2025","journal-title":"J. Ethnopharm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s11010-023-04768-2","article-title":"Epigallocatechin-3-gallate restores mitochondrial homeostasis impairment by inhibiting HDAC1-mediated NRF1 histone deacetylation in cardiac hypertrophy","volume":"479","author":"Li","year":"2024","journal-title":"Molec. Cell. Biochem."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Xu, X., Liu, S., Wang, X., Musha, J., Li, T., and Zhan, J. (2025). Butyrate inhibits histone deacetylase 2 expression to alleviate liver fibrosis in biliary atresia. BMC Pediatrics, 25.","DOI":"10.1186\/s12887-025-05635-3"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"25748","DOI":"10.1074\/jbc.M111871200","article-title":"Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family","volume":"277","author":"Gao","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Wang, L., Bai, Y., Cao, Z., Guo, Z., Lian, Y., Liu, P., and Chen, Q. (2024). Histone deacetylases and inhibitors in diabetes mellitus and its complications. Biomed. Pharmacother., 177.","DOI":"10.1016\/j.biopha.2024.117010"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Choi, M.A., Park, S.Y., Chae, H.Y., Song, Y., Sharma, C., and Seo, Y.H. (2019). Design, synthesis and biological evaluation of a series of CNS penetrant HDAC inhibitors structurally derived from amyloid-\u03b2 probes. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-49784-9"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40265-024-02052-1","article-title":"Givinostat: First approval","volume":"84","author":"Lamb","year":"2024","journal-title":"Drugs"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-23-3171","article-title":"A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAF V600-Mutated Melanoma","volume":"30","author":"Embaby","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/17568919.2024.2437975","article-title":"A short overview of dual targeting HDAC inhibitors","volume":"17","author":"Liu","year":"2025","journal-title":"Future Med. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.clml.2024.11.015","article-title":"A Phase I Study of Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone in Patients with Relapsed or Refractory Aggressive Lymphomas Enriched for T-Cell Lymphomas","volume":"25","author":"Foley","year":"2025","journal-title":"Clin. Lymph. Myel. Leuk."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Seane, E.N., Nair, S., Vandevoorde, C., and Joubert, A. (2024). Mechanistic Sequence of Histone Deacetylase Inhibitors and Radiation Treatment: An Overview. Pharmaceuticals, 17.","DOI":"10.20944\/preprints202404.0176.v1"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"115938","DOI":"10.1016\/j.ejmech.2023.115938","article-title":"Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment","volume":"263","author":"Shirbhate","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"107043","DOI":"10.1016\/j.ejps.2025.107043","article-title":"Enhancement of the in vitro anti-leukemic effect of the histone deacetylase inhibitor Romidepsin using Poly-(D, L-lactide-co-glycolide) nanoparticles as a drug carrier","volume":"207","author":"Aroonthongsawat","year":"2025","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Han, R., Zhou, H., Peng, B., Yu, S., Zhu, J., and Chen, J. (2025). Synergistic Integration of HDAC Inhibitors and Individualized Neoantigen Therapy (INT): A Next-Generation Combinatorial Approach for Cancer Immunotherapy. Vaccines, 13.","DOI":"10.3390\/vaccines13060550"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13148-025-01841-z","article-title":"Advances in epigenetic treatment of adult T-cell leukemia\/lymphoma: A comprehensive review","volume":"17","author":"Letafati","year":"2025","journal-title":"Clin. Epigenet"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Tian, J., Han, M., Song, F., Liu, Y., Shen, Y., and Zhong, J. (2025). Advances of HDAC inhibitors in tumor therapy: Potential applications through immune modulation. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1576781"},{"key":"ref_30","first-page":"1398","article-title":"The Combination Effects of Vorinostat and Silver Nanoparticles Targeting Angiogenesis, Oxidative Stress, and Inflammation: An In Vitro Study","volume":"7","author":"Alqaraleh","year":"2024","journal-title":"J. Med. Chem. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10637-007-9075-2","article-title":"Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza\u2122, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and\/or metastatic head and neck cancer","volume":"26","author":"Blumenschein","year":"2008","journal-title":"Investig. New Drugs"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1182\/blood.V122.21.4385.4385","article-title":"Romidepsin Is Effective and Well-Tolerated in Patients\u2265 60 Years Old with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL): Analysis from Phase 2 Trials","volume":"122","author":"Shustov","year":"2013","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s12017-021-08660-4","article-title":"Repurposing vorinostat for the treatment of disorders affecting brain","volume":"23","author":"Athira","year":"2021","journal-title":"Neuromol. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00408-025-00798-3","article-title":"The Role of HDAC3 in Pulmonary Diseases","volume":"203","author":"Hong","year":"2025","journal-title":"Lung"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"107057","DOI":"10.1016\/j.ejps.2025.107057","article-title":"Clinical efficacy and mechanistic insights of FDA-approved HDAC inhibitors in the treatment of lymphoma","volume":"208","author":"Bakrim","year":"2025","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e202405484","DOI":"10.1002\/slct.202405484","article-title":"Clinical Applications of HDAC Inhibitors as Anticancer Agents in Prostate, Breast, Ovarian, and Cervical Cancers","volume":"10","author":"Bakrim","year":"2025","journal-title":"ChemistrySelect"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"177620","DOI":"10.1016\/j.ejphar.2025.177620","article-title":"Harnessing histone deacetylase inhibitors for enhanced cancer immunotherapy","volume":"997","author":"Hedayat","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Luo, Q., Gu, L., Tian, X., Zhao, Y., Zhang, Y., and Wang, F. (2025). Histone Deacetylase Inhibitors Promote the Anticancer Activity of Cisplatin: Mechanisms and Potential. Pharmaceuticals, 18.","DOI":"10.3390\/ph18040563"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/14737140.2025.2458156","article-title":"Synergistic strategies: Histone deacetylase inhibitors and platinum-based drugs in cancer therapy","volume":"25","author":"Shirbhate","year":"2025","journal-title":"Exp. Rev. Antican. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40164-024-00507-5","article-title":"Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: Mechanisms, therapeutic implications, and future perspectives","volume":"13","author":"Pu","year":"2024","journal-title":"Experim. Hemato. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"104052","DOI":"10.1016\/j.drudis.2024.104052","article-title":"Restoring the epigenome in Alzheimer\u2019s disease: Advancing HDAC inhibitors as therapeutic agents","volume":"29","author":"Pereira","year":"2024","journal-title":"Drug Discov. Today"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer\u2019s disease: Mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"103878","DOI":"10.1016\/j.drudis.2024.103878","article-title":"Recent discoveries of the role of histone modifications and related inhibitors in pathological cardiac hypertrophy","volume":"29","author":"Wu","year":"2024","journal-title":"Drug Discov. Today"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"120946","DOI":"10.1016\/j.lfs.2022.120946","article-title":"Current trends in development of HDAC-based chemotherapeutics","volume":"308","author":"Cheshmazar","year":"2022","journal-title":"Life Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1080\/14756366.2017.1417274","article-title":"Zinc binding groups for histone deacetylase inhibitors","volume":"33","author":"Zhang","year":"2018","journal-title":"J. Enz. Inhib. Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.chembiol.2014.12.015","article-title":"Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases","volume":"22","author":"Wang","year":"2015","journal-title":"Chem. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/cmdc.202000934","article-title":"Strategies to design selective histone deacetylase inhibitors","volume":"16","author":"Melesina","year":"2021","journal-title":"ChemMedChem"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Luo, Y., Yan, Z., Chu, X., Zhang, Y., Qiu, Y., and Li, H. (2025). Binding mechanism and distant regulation of histone deacetylase 8 by PCI-34051. Commun. Biol., 8.","DOI":"10.1038\/s42003-025-07649-0"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Routholla, G., Pulya, S., Patel, T., Amin, S.A., Adhikari, N., Biswas, S., and Ghosh, B. (2021). Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors. Bioorg. Chem., 114.","DOI":"10.1016\/j.bioorg.2021.105050"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Neganova, M., Aleksandrova, Y., Suslov, E., Mozhaitsev, E., Munkuev, A., Tsypyshev, D., Chicheva, M., Rogachev, A., Sukocheva, O., and Volcho, K. (2021). Novel Multitarget Hydroxamic Acids with a Natural Origin CAP Group against Alzheimer\u2019s Disease: Synthesis, Docking and Biological Evaluation. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13111893"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Aleksandrova, Y., Munkuev, A., Mozhaitsev, E., Suslov, E., Tsypyshev, D., Chaprov, K., Begunov, R., Volcho, K., Salakhutdinov, N., and Neganova, M. (2023). Elaboration of the Effective Multi-Target Therapeutic Platform for the Treatment of Alzheimer\u2019s Disease Based on Novel Monoterpene-Derived Hydroxamic Acids. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119743"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Aleksandrova, Y., Munkuev, A., Mozhaitsev, E., Suslov, E., Volcho, K., Salakhutdinov, N., and Neganova, M. (2023). Hydroxamic Acids Containing a Bicyclic Pinane Backbone as Epigenetic and Metabolic Regulators: Synergizing Agents to Overcome Cisplatin Resistance. Cancers, 15.","DOI":"10.3390\/cancers15204985"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/gutjnl-2022-327736","article-title":"Global burden of colorectal cancer in 2020 and 2040: Incidence and mortality estimates from GLOBOCAN","volume":"72","author":"Morgan","year":"2023","journal-title":"Gut"},{"key":"ref_54","first-page":"10","article-title":"Cancer statistics","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.2741\/4847","article-title":"Epigenetic alterations in cancer","volume":"25","author":"Ilango","year":"2020","journal-title":"Front. Biosci. Land."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Obidiro, O., Battogtokh, G., and Akala, E.O. (2023). Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook. Pharmaceutics, 15.","DOI":"10.20944\/preprints202306.0074.v1"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s10549-020-06083-6","article-title":"Global, regional, national burden of breast cancer in 185 countries: Evidence from GLOBOCAN 2018","volume":"187","author":"Sharma","year":"2021","journal-title":"Breast Canc. Res. Treat."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s13346-024-01648-0","article-title":"A comprehensive review on doxorubicin: Mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer","volume":"15","author":"Bisht","year":"2025","journal-title":"Drug Deliv. Trans. Res."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Yudaev, P., Tupikov, A., and Chistyakov, E. (2025). Organocyclophosphazenes and Materials Based on Them for Pharmaceuticals and Biomedicine. Biomolecules, 15.","DOI":"10.3390\/biom15020262"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Lehmann, U. (2024). Epigenetic Therapies in Triple-Negative Breast Cancer: Concepts, Visions, and Challenges. Cancers, 16.","DOI":"10.3390\/cancers16122164"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Alothaim, T., Charbonneau, M., and Tang, X. (2021). HDAC6 inhibitors sensitize non-mesenchymal triple-negative breast cancer cells to cysteine deprivation. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-90527-6"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"117634","DOI":"10.1016\/j.ejmech.2025.117634","article-title":"Challenging Triple Negative Breast Cancer through HDAC6 selective inhibition: Novel cap-group identification, structure-activity relationships, computational and biological studies","volume":"292","author":"Barone","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"117636","DOI":"10.1016\/j.ejmech.2025.117636","article-title":"Design and synthesis of pyridine-based benzamides as potent HDAC3 inhibitors as an armament against breast cancer with in vivo validation","volume":"291","author":"Himaja","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Chen, X., Li, R., Qiu, Y., Lin, F., Chen, S., Li, X., and Fang, M. (2025). Design, synthesis, and biological evaluation of N-(2-amino-phenyl)-5-(4-aryl-pyrimidin-2-yl) amino)-1H-indole-2-carboxamide derivatives as novel inhibitors of CDK9 and class I HDACs for cancer treatment. Bioorg. Chem., 162, Erratum in Bioorg. Chem. 2025, 163, 108657.","DOI":"10.1016\/j.bioorg.2025.108657"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cell.2012.08.026","article-title":"Transcriptional amplification in tumor cells with elevated c-Myc","volume":"151","author":"Lin","year":"2012","journal-title":"Cell"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"0670","DOI":"10.34133\/research.0670","article-title":"Discovery of a Novel Selective PAK1\/HDAC6\/HDAC10 Inhibitor ZMF-25 that Induces Mitochondrial Metabolic Breakdown and Autophagy-Related Cell Death in Triple-Negative Breast Cancer","volume":"8","author":"Zhang","year":"2025","journal-title":"Research"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(23)02705-8","article-title":"B-cell non-Hodgkin lymphomas","volume":"403","author":"Silkenstedt","year":"2024","journal-title":"Lancet"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e33052","DOI":"10.1016\/j.heliyon.2024.e33052","article-title":"Stochasticity of anticancer mechanisms underlying clinical effectiveness of vorinostat","volume":"10","author":"Khalid","year":"2024","journal-title":"Heliyon"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clml.2014.01.007","article-title":"Status of PI3K\/Akt\/mTOR pathway inhibitors in lymphoma","volume":"14","author":"Westin","year":"2014","journal-title":"Clin. Lymph. Myel. Leuk."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"117658","DOI":"10.1016\/j.ejmech.2025.117658","article-title":"Discovery of hydrazide-based PI3K\/HDAC dual inhibitors with enhanced pro-apoptotic activity in lymphoma cells","volume":"292","author":"Hou","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/jnci\/djj133","article-title":"Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor","volume":"98","author":"Yaguchi","year":"2006","journal-title":"J. Nat. Canc. Inst."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"117852","DOI":"10.1016\/j.ejmech.2025.117852","article-title":"Design, synthesis, and biological evaluation of novel PI3K\u03b4\/HDAC6 dual inhibitors for the treatment of non-Hodgkin\u2019s lymphoma","volume":"296","author":"Zuo","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_75","first-page":"1","article-title":"WT161, a selective HDAC6 inhibitor, decreases growth, enhances chemosensitivity, promotes apoptosis, and suppresses motility of melanoma cells","volume":"95","author":"Oliveira","year":"2025","journal-title":"Cancer Chem. Pharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"117601","DOI":"10.1016\/j.ejmech.2025.117601","article-title":"Design, synthesis and bioevaluation of novel hydrazide derivatives as enhancers of immunotherapy and DNA-damage response in antitumor therapy","volume":"291","author":"Hu","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"8124","DOI":"10.1021\/acs.jmedchem.4c02550","article-title":"HDAC11 Inhibition as a Potential Therapeutic Strategy for AML: Target Identification, Lead Discovery, Antitumor Potency, and Mechanism Investigation","volume":"68","author":"Yang","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e2400889","DOI":"10.1002\/ardp.202400889","article-title":"New potent N-hydroxycinnamamide-based histone deacetylase inhibitors suppress proliferation and trigger apoptosis in THP-1 leukaemia cells","volume":"358","author":"Onuscakova","year":"2025","journal-title":"Archiv. Pharmaz."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"116447","DOI":"10.1016\/j.ejmech.2024.116447","article-title":"Preferential HDAC6 inhibitors derived from HPOB exhibit synergistic antileukemia activity in combination with decitabine","volume":"272","author":"Tretbar","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Hemida, N., ElGamil, D.S., ElHady, A.K., Lin, K.C., Chang, Y.H., Hilscher, S., and Abdel-Halim, M. (2025). Unlocking the potential of novel tetrahydro-\u03b2-carboline-based HDAC6 inhibitors for colorectal cancer therapy: Design, synthesis and biological evaluation. Bioorg. Chem., 160.","DOI":"10.1016\/j.bioorg.2025.108454"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"111817","DOI":"10.1016\/j.cellsig.2025.111817","article-title":"TDH-11 inhibits the proliferation and colonization of colorectal cancer by reducing the activity of HDAC","volume":"132","author":"Zhong","year":"2025","journal-title":"Cell. Signal."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2406025","DOI":"10.1080\/14756366.2024.2406025","article-title":"Synthesis and biological evaluation of ortho-phenyl phenylhydroxamic acids containing phenothiazine with improved selectivity for class IIa histone deacetylases","volume":"39","author":"Hsu","year":"2024","journal-title":"J. Enz. Inhibit. Med. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1007\/s00044-025-03418-0","article-title":"Exploring putative histone deacetylase inhibitors with antiproliferative activity of chrysin derivatives","volume":"34","author":"Kamloon","year":"2025","journal-title":"Med. Chem. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s44220-023-00191-0","article-title":"Alzheimer\u2019s disease risk reduction in clinical practice: A priority in the emerging field of preventive neurology","volume":"2","author":"Niotis","year":"2024","journal-title":"Nat. Ment. Health"},{"key":"ref_85","unstructured":"World Health Organization (2017). Global action plan on the public health response to dementia 2017\u20132025. Global Action Plan on the Public Health Response to Dementia 2017\u20132025, World Health Organization."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"117912","DOI":"10.1016\/j.lfs.2020.117912","article-title":"Identification of novel class I and class IIb histone deacetylase inhibitor for Alzheimer\u2019s disease therapeutics","volume":"256","author":"Gupta","year":"2020","journal-title":"Life Sci."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Lu, X., Wang, L., Yu, C., Yu, D., and Yu, G. (2015). Histone acetylation modifiers in the pathogenesis of Alzheimer\u2019s disease. Front. Cell. Neurosci., 9.","DOI":"10.3389\/fncel.2015.00226"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/npp.2016.163","article-title":"A first-in-class small-molecule that acts as a dual inhibitor of HDAC and PDE5 and that rescues hippocampal synaptic impairment in Alzheimer\u2019s disease mice","volume":"42","author":"Rabal","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"112746","DOI":"10.1016\/j.exger.2025.112746","article-title":"Effects of Bufexamac, a class IIb HDAC inhibitor, on behavior and neuropathological features in an A\u03b2-induced rat model of Alzheimer\u2019s disease","volume":"204","author":"Mirehei","year":"2025","journal-title":"Experim. Gerontol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"113821","DOI":"10.1016\/j.ejmech.2021.113821","article-title":"Synthesis and biological evaluation of selective histone deacetylase 6 inhibitors as multifunctional agents against Alzheimer\u2019s disease","volume":"225","author":"Wang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"115817","DOI":"10.1016\/j.ejmech.2023.115817","article-title":"Targeting protein kinases for the treatment of Alzheimer\u2019s disease: Recent progress and future perspectives","volume":"261","author":"Li","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"136044","DOI":"10.1016\/j.neulet.2021.136044","article-title":"Minireview: Lithium: A therapeutic option in Alzheimer\u2019s disease and its prodromal stages?","volume":"760","author":"Haussmann","year":"2021","journal-title":"Neurosci. Lett."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"177605","DOI":"10.1016\/j.ejphar.2025.177605","article-title":"Anti-Alzheimer effects of an HDAC6 inhibitor, WY118, alone and in combination of lithium chloride: Synergistic suppression of ferroptosis via the modulation of tau phosphorylation and MAPK signaling","volume":"997","author":"Lu","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.7150\/thno.54589","article-title":"Longitudinal evaluation of a novel BChE PET tracer as an early in vivo biomarker in the brain of a mouse model for Alzheimer disease","volume":"11","author":"Rejc","year":"2021","journal-title":"Theranos."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Lv, B., Wang, Z., Wang, Q., Xu, Z., Tang, J., Pei, Y., and Chen, Y. (2025). Dual inhibitors of butyrylcholinesterase and histone deacetylase 6 for the treatment of Alzheimer\u2019s disease: Design, synthesis, and biological evaluation. Bioorg. Med. Chem., 127.","DOI":"10.1016\/j.bmc.2025.118219"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40820-022-00847-z","article-title":"Anti-Parkinsonian therapy: Strategies for crossing the blood\u2013brain barrier and nano-biological effects of nanomaterials","volume":"14","author":"Cheng","year":"2022","journal-title":"Nano-Micro Lett."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2105152","DOI":"10.1002\/adfm.202105152","article-title":"Treating LRRK2-related Parkinson\u2019s disease by inhibiting the mTOR signaling pathway to restore autophagy","volume":"31","author":"Cui","year":"2021","journal-title":"Adv. Func. Mater."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"110319","DOI":"10.1016\/j.neuropharm.2025.110319","article-title":"The class-IIa HDAC inhibitor TMP269 promotes BMP-Smad signalling and is neuroprotective in in vitro and in vivo 6-hydroxydopamine models of Parkinson\u2019s disease","volume":"268","author":"Mazzocchi","year":"2025","journal-title":"Neuropharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e70057","DOI":"10.1002\/prp2.70057","article-title":"HDAC4\/5 Inhibitor, LMK-235 Improves Animal Voluntary Movement in MPTP-Induced Parkinson\u2019s Disease Model","volume":"13","author":"Lee","year":"2025","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Pham, K.Y., Khanal, S., Bohara, G., Rimal, N., Song, S.H., Nguyen, T.T.K., and Yook, S. (2025). HDAC6 inhibitor-loaded brain-targeted nanocarrier-mediated neuroprotection in methamphetamine-driven Parkinson\u2019s disease. Redox Biol., 79.","DOI":"10.1016\/j.redox.2024.103457"},{"key":"ref_101","first-page":"935","article-title":"Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: Trials and tribulations","volume":"38","author":"Hausenloy","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1248\/bpb.b18-00785","article-title":"Histone deacetylase inhibitor SAHA treatment prevents the development of heart failure after myocardial infarction via an induction of heat-shock proteins in rats","volume":"42","author":"Nagata","year":"2019","journal-title":"Biol. Pharm. Bull."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"110448","DOI":"10.1016\/j.isci.2024.110448","article-title":"Corosolic acid attenuates cardiac ischemia\/reperfusion injury through the PHB2\/PINK1\/parkin\/mitophagy pathway","volume":"27","author":"Zhang","year":"2024","journal-title":"Iscience"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"107466","DOI":"10.1016\/j.phrs.2024.107466","article-title":"The PINK1\/Parkin signaling pathway-mediated mitophagy: A forgotten protagonist in myocardial ischemia\/reperfusion injury","volume":"209","author":"Zhao","year":"2024","journal-title":"Pharmacol. Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.apsb.2021.07.003","article-title":"Histone deacetylase inhibitors inhibit cervical cancer growth through Parkin acetylation-mediated mitophagy","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharmaceut. Sin."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/path.6419","article-title":"Histone deacetylase 6 inhibition attenuates pathological cardiac hypertrophy by promoting autophagy through MAP1LC3B ubiquitination","volume":"266","author":"Yao","year":"2025","journal-title":"J. Pathol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4070\/kcj.2024.0093","article-title":"YAK577 Attenuates Cardiac Remodeling and Fibrosis in Isoproterenol-Infused Heart Failure Mice by Downregulating MMP12","volume":"55","author":"Zhou","year":"2024","journal-title":"Korean Circul. J."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Miksiunas, R., Rucinskas, K., Janusauskas, V., Labeit, S., and Bironaite, D. (2020). Histone deacetylase inhibitor suberoylanilide hydroxamic acid improves energetic status and cardiomyogenic differentiation of human dilated myocardium-derived primary mesenchymal cells. Inter. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21144845"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s12011-021-02659-5","article-title":"Selenium-based novel epigenetic regulators offer effective chemotherapeutic alternative with wider safety margins in experimental colorectal cancer","volume":"200","author":"Ghanghas","year":"2022","journal-title":"Biol. Trace Elem. Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"116957","DOI":"10.1016\/j.taap.2024.116957","article-title":"A novel histone deacetylase inhibitor Se-SAHA attenuates isoproterenol-induced heart failure via antioxidative stress and autophagy inhibition","volume":"487","author":"Cheng","year":"2024","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Evans, L.W., Bender, A., Burnett, L., Godoy, L., Shen, Y., Staten, D., and Ferguson, B.S. (2020). Emodin and emodin-rich rhubarb inhibits histone deacetylase (HDAC) activity and cardiac myocyte hypertrophy. J. Nutrit. Biochem., 79.","DOI":"10.1016\/j.jnutbio.2019.108339"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2412903","DOI":"10.1002\/advs.202412903","article-title":"Targeting Histone Deacetylase 11 with a Highly Selective Inhibitor for the Treatment of MASLD","volume":"12","author":"Zhang","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"101274","DOI":"10.1016\/j.molmet.2021.101274","article-title":"NAFLD-a rising metabolic disease","volume":"50","author":"Zeigerer","year":"2021","journal-title":"Mol. Met."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1021\/acschembio.7b00942","article-title":"Histone deacetylase 11 is a fatty-acid deacylase","volume":"13","author":"Kutil","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1021\/acschembio.2c00840","article-title":"Trapoxin A analogue as a selective nanomolar inhibitor of HDAC11","volume":"18","author":"Ho","year":"2023","journal-title":"ACS Chem. Biol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"16075","DOI":"10.1021\/acs.jmedchem.3c01491","article-title":"Development and pharmacochemical characterization discover a novel brain-permeable HDAC11-selective inhibitor with therapeutic potential by regulating neuroinflammation in mice","volume":"66","author":"Bai","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"17335","DOI":"10.1073\/pnas.0706487104","article-title":"Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases","volume":"104","author":"Lahm","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"230127","DOI":"10.1183\/16000617.0127-2023","article-title":"The evolution of in vitro models of lung fibrosis: Promising prospects for drug discovery","volume":"33","author":"Kolanko","year":"2024","journal-title":"Eur. Resp. Rev."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.pupt.2017.08.012","article-title":"Lung fibrosis-associated soluble mediators and bronchoalveolar lavage from idiopathic pulmonary fibrosis patients promote the expression of fibrogenic factors in subepithelial lung myofibroblasts","volume":"46","author":"Bouros","year":"2017","journal-title":"Pulm. Pharmacol. Therapeut."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1189\/jlb.1013565","article-title":"Histone deacetylase isoforms regulate innate immune responses by deacetylating mitogen-activated protein kinase phosphatase-1","volume":"95","author":"Jeong","year":"2014","journal-title":"J. Leukoc. Biol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"176711","DOI":"10.1016\/j.ejphar.2024.176711","article-title":"MPT0E028, a novel pan-HDAC inhibitor, prevents pulmonary fibrosis through inhibition of TGF-\u03b2-induced CTGF expression in human lung fibroblasts: Involvement of MKP-1 activation","volume":"977","author":"Liu","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Gao, Y., Wang, P., Hu, Z., Cui, H., Chen, X., Wang, L., and Yao, Y. (2024). Design, synthesis, and evaluation of a novel TRAIL-activated HDAC6 inhibitor for the treatment of pulmonary fibrosis. Bioorg. Med. Chem., 113.","DOI":"10.1016\/j.bmc.2024.117924"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Li, Y., Quan, J., Song, H., Li, D., Ma, E., Wang, Y., and Ma, C. (2021). Novel pyrrolo [2, 1-c][1, 4] benzodiazepine-3, 11-dione (PBD) derivatives as selective HDAC6 inhibitors to suppress tumor metastasis and invasion in vitro and in vivo. Bioorg. Chem., 114.","DOI":"10.1016\/j.bioorg.2021.105081"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1021\/acsptsci.4c00456","article-title":"Spirotetrahydroisoquinoline-Based Histone Deacetylase Inhibitors as New Antifibrotic Agents: Biological Evaluation in Human Fibroblasts from Bronchoalveolar Lavages of Idiopathic Pulmonary Fibrosis Patients","volume":"8","author":"Fontana","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"6767","DOI":"10.1038\/s41467-023-42477-y","article-title":"Single-atom catalysts-based catalytic ROS clearance for efficient psoriasis treatment and relapse prevention via restoring ESR1","volume":"14","author":"Lu","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1080\/14740338.2020.1785427","article-title":"Biologics in the treatment of pustular psoriasis","volume":"19","author":"Wang","year":"2020","journal-title":"Exp. Opin. Drug Safety"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Gavra, D.I., K\u00f3sa, D., Pet\u0151, \u00c1., J\u00f3zsa, L., Ujhelyi, Z., Feh\u00e9r, P., and B\u00e1cskay, I. (2024). Exploring the Correlation between the PASI and DLQI Scores in Psoriasis Treatment with Topical Ointments Containing Rosa\u00d7 damascena Mill. Extract. Pharmaceuticals, 17.","DOI":"10.3390\/ph17081092"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Asmamaw, M.D., He, A., Zhang, L.R., Liu, H.M., and Gao, Y. (2024). Histone deacetylase complexes: Structure, regulation and function. Biochim. Biophys. Acta Rev. Cancer., 1879.","DOI":"10.1016\/j.bbcan.2024.189150"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jdermsci.2023.05.001","article-title":"Topical histone deacetylase 1 inhibitor entinostat ameliorates psoriasiform dermatitis through suppression of IL-17A response","volume":"110","author":"Jiang","year":"2023","journal-title":"J. Dermatol. Sci."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-025-06544-w","article-title":"Inhibition of histone deacetylases 3 attenuates imiquimod-induced psoriatic dermatitis via targeting cGAS-STING signaling in keratinocytes","volume":"23","author":"Zeng","year":"2025","journal-title":"J. Trans. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"19267","DOI":"10.1021\/acs.jmedchem.4c01681","article-title":"Discovery of Janus Kinase and Histone Deacetylase Dual Inhibitors as a New Strategy to Treat Psoriasis","volume":"67","author":"Hu","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17568919.2025.2533113","article-title":"Epigenetic therapy meets targeted protein degradation: HDAC-PROTACs in cancer treatment","volume":"17","author":"Hussain","year":"2025","journal-title":"Future Med. Chem."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"115746","DOI":"10.1016\/j.ejmech.2023.115746","article-title":"The application of PROTAC in HDAC","volume":"260","author":"Chen","year":"2023","journal-title":"Eur. J. Med. Chem."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/17\/8629\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:39:40Z","timestamp":1760035180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/17\/8629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":134,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["ijms26178629"],"URL":"https:\/\/doi.org\/10.3390\/ijms26178629","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]}}}